Previously, I have presented on the discovery of pharmacogenomics regulatory variants with the Pharmacoepigenomics Informatics Pipeline (PIP). Now, I will present on the results of the second experiment with this pipeline where it was applied to warfarin pharmacogenomics. This experiment aimed to discover whether the PIP methods had utility outside of neuropsychiatry. It revealed that they do, but also that the current PIP has serious trouble discovering pharmacokinetic variants. I will also present the work-in-progress PIP version 1.1, which is designed to offer greater explanatory power and differentiate multiple related phenotypes by using more epigenome and 4D nucleome datasets and methods. I'll cover the overall planned feature set, and a couple of different modules currently being worked on by a few different people, including my epigenome dashboard SVM module, Nick Reamaroon's QTL module, and Gordon Fon's input module.